Dexcom shareholders approve equity plan share increases and elect nine directors
At its May 8, 2025 annual meeting, Dexcom stockholders approved amendments that add 3,400,000 shares to the Amended and Restated 2015 Equity Incentive Plan and 8,000,000 shares to the Amended and Restated 2015 Employee Stock Purchase Plan, elected nine directors, and approved executive compensation on an advisory basis. The board also reduced its size to nine directors effective May 8, 2025. The share increases enlarge the pool available for employee equity awards.
Key points
- Equity Incentive Plan share reserve increased by 3,400,000 shares; Employee Stock Purchase Plan share reserve increased by 8,000,000 shares
- All nine director nominees were elected to serve until the 2026 annual meeting
- Advisory say-on-pay vote: 290,471,904 votes for and 33,807,214 against
- Board size reduced to nine directors effective May 8, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 09, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.